FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324057709> ?p ?o ?g. }

• W4324057709 endingPage "s162" @default.
• W4324057709 startingPage "s162" @default.
• W4324057709 abstract "Introduction: Actinic Keratosis (AK) are epidermal lesions with potential to progress to squamous cell carcinomas if left untreated. AKs have also been shown to negatively affect emotional functioning and skin-related quality of life of patients. The primary objective of the analysis was to evaluate IGA success at Week-8, and clinician-reported likelihood to consider tirbanibulin again for future treatments, among patients with AKs administered tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AKs on the face or scalp who were newly initiated with tirbanibulin treatment in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, Week-8 (timeframe for main endpoints) and Week-24. Clinicians assessed AK responses using an IGA on a five-point adjectival response scale of 0 (completely cleared), 1 (partially cleared), 2 (moderately cleared), 3 (minimally cleared) and 4 (not cleared). IGA success was defined as achieving an IGA score of 0 or 1 at Week-8. Clinicians also reported their likelihood to reuse tirbanibulin treatment for their patients, as a surrogate measure of satisfaction with the treatment. Results: A total of 290 AK patients completed the study assessments at Week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). At Week-8, proportion of patients with completely/partially cleared AK (Approximately 75-100% clearance of AK lesions in the treated area, IGA 1/0) was 73.79%; moderately cleared (IGA 2) was 17.24%, and minimally cleared/not cleared (IGA 3/4) was 8.97%. Correspondingly, IGA success in this cohort of patients treated with tirbanibulin was 73.79%. Proportion of patients for whom clinicians noted that they would ‘somewhat or very likely’ consider tirbanibulin treatment again, if need arises, was 85.17%, with 7.59% reporting a neutral response, and 7.24% reporting ‘somewhat or very unlikely’ to consider treatment with tirbanibulin again. Conclusion: Overwhelming majority of patients with AK using tirbanibulin experienced IGA success at Week-8, and an overwhelming majority of clinicians reported their desire to consider tirbanibulin again to treat AK lesions for their patients." @default.
• W4324057709 created "2023-03-14" @default.
• W4324057709 creator A5000062355 @default.
• W4324057709 creator A5003122683 @default.
• W4324057709 creator A5005978143 @default.
• W4324057709 creator A5019624446 @default.
• W4324057709 creator A5033903141 @default.
• W4324057709 creator A5038505651 @default.
• W4324057709 creator A5052142462 @default.
• W4324057709 creator A5058903008 @default.
• W4324057709 creator A5069880241 @default.
• W4324057709 creator A5076016430 @default.
• W4324057709 creator A5083367910 @default.
• W4324057709 creator A5083547509 @default.
• W4324057709 date "2023-03-13" @default.
• W4324057709 modified "2023-10-16" @default.
• W4324057709 title "Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)" @default.
• W4324057709 doi "https://doi.org/10.25251/skin.7.supp.162" @default.
• W4324057709 hasPublicationYear "2023" @default.
• W4324057709 type Work @default.
• W4324057709 citedByCount "0" @default.
• W4324057709 crossrefType "journal-article" @default.
• W4324057709 hasAuthorship W4324057709A5000062355 @default.
• W4324057709 hasAuthorship W4324057709A5003122683 @default.
• W4324057709 hasAuthorship W4324057709A5005978143 @default.
• W4324057709 hasAuthorship W4324057709A5019624446 @default.
• W4324057709 hasAuthorship W4324057709A5033903141 @default.
• W4324057709 hasAuthorship W4324057709A5038505651 @default.
• W4324057709 hasAuthorship W4324057709A5052142462 @default.
• W4324057709 hasAuthorship W4324057709A5058903008 @default.
• W4324057709 hasAuthorship W4324057709A5069880241 @default.
• W4324057709 hasAuthorship W4324057709A5076016430 @default.
• W4324057709 hasAuthorship W4324057709A5083367910 @default.
• W4324057709 hasAuthorship W4324057709A5083547509 @default.
• W4324057709 hasBestOaLocation W43240577091 @default.
• W4324057709 hasConcept C126322002 @default.
• W4324057709 hasConcept C126894567 @default.
• W4324057709 hasConcept C138944611 @default.
• W4324057709 hasConcept C160798450 @default.
• W4324057709 hasConcept C188816634 @default.
• W4324057709 hasConcept C2777873816 @default.
• W4324057709 hasConcept C3019992690 @default.
• W4324057709 hasConcept C71924100 @default.
• W4324057709 hasConceptScore W4324057709C126322002 @default.
• W4324057709 hasConceptScore W4324057709C126894567 @default.
• W4324057709 hasConceptScore W4324057709C138944611 @default.
• W4324057709 hasConceptScore W4324057709C160798450 @default.
• W4324057709 hasConceptScore W4324057709C188816634 @default.
• W4324057709 hasConceptScore W4324057709C2777873816 @default.
• W4324057709 hasConceptScore W4324057709C3019992690 @default.
• W4324057709 hasConceptScore W4324057709C71924100 @default.
• W4324057709 hasIssue "2" @default.
• W4324057709 hasLocation W43240577091 @default.
• W4324057709 hasOpenAccess W4324057709 @default.
• W4324057709 hasPrimaryLocation W43240577091 @default.
• W4324057709 hasRelatedWork W168688824 @default.
• W4324057709 hasRelatedWork W1980598822 @default.
• W4324057709 hasRelatedWork W1981434988 @default.
• W4324057709 hasRelatedWork W2038091365 @default.
• W4324057709 hasRelatedWork W2219582016 @default.
• W4324057709 hasRelatedWork W2809395715 @default.
• W4324057709 hasRelatedWork W3120903604 @default.
• W4324057709 hasRelatedWork W4205647419 @default.
• W4324057709 hasRelatedWork W4246001502 @default.
• W4324057709 hasRelatedWork W190566632 @default.
• W4324057709 hasVolume "7" @default.
• W4324057709 isParatext "false" @default.
• W4324057709 isRetracted "false" @default.
• W4324057709 workType "article" @default.